NICE recommends maintenance olaparib for relapsed, platinum-sensitive ovarian cancer

  • National Institute for Health and Care Excellence
  • National Institute for Health and Care Excellence
  • 16 Jan 2020

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

Key recommendations

  • Olaparib is recommended as an option for maintenance treatment if the patient harbors a BRCA1/2 mutation and has received ≥3 lines of platinum-based chemotherapy.
    • Olaparib meets NICE's end-of-life criteria for this recommendation, and it is cost-effective and therefore recommended for routine use.
  • Olaparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment in patients with BRCA1/2 mutation who have received 2 prior lines of platinum-based chemotherapy and if the conditions in the managed access agreement for olaparib are followed.
    • Olaparib does not meet NICE's end-of-life criteria for this recommendation; the cost-effectiveness estimates are uncertain because OS data are not yet available.